TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23281759
Drug: 0.18 mg
Normalized name: naloxone 0.18 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.18 mg biotin/kg
Study: 23281759
Drug: 0.21 mg
Normalized name: albuterol 0.21 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.21 mg biotin/kg
Study: 20731476
Drug: Guanfacine ER
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine ER (1-4 mg once daily)
Study: 17035721
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement + topical formulations
Study: 11214732
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dietary supplement)
Study: 3031154
Drug: Oral dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dextroamphetamine with oral thymoxamine (alpha‐noradrenergic antagonist)
Study: 26827250
Drug: SHUTi (online
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHUTi (online insomnia program based on cognitive behavioural therapy for insomnia)
Study: 16238587
Drug: Salbutamol/fluticasone 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol/fluticasone 500 microg/dose, each combined dose administered every 15 min
Study: 30909945
Drug: AA supplement
Normalized name: Amino Acids Oral Powder for Suspension [EAA SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA supplement for 15 days prior to the race
Study: 30909945
Drug: Non-AA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-AA group (no supplement)
Study: 25775052
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus tirofiban
Study: 11108748
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue plasminogen activator (rtPA)
Study: 19879462
Drug: Clinical assessment
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical assessment to guide therapy
Study: 7483087
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine hydrochloride (100 mg IV twice daily for four days, followed by 150 mg orally twice daily for five days)
Study: 20029974
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant treatment (Control)
Study: 2106334
Drug: Prostacyclin (PGI2)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (PGI2) infusion before and during CPB
Study: 2109927
Drug: Prostacyclin (PGI2)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (PGI2) infusion
Study: 6117681
Drug: Neither antibiotics
Normalized name: 2,2',3,3',4,4',5,5',6-nonachlorodiphenyl either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neither antibiotics nor myringotomy
Study: 6117681
Drug: Both antibiotics
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both antibiotics and myringotomy
Study: 23541571
Drug: Elevated pretreatment
Normalized name: minoxidil
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elevated pretreatment serum LDH level (≥245.0 U/L)
Study: 17109335
Drug: Vaccine (rAd5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (rAd5 vector HIV-1 candidate vaccine) at dose levels of 10^9 (n=10), 10^10 (n=10), or 10^11 (n=10) particle units
Study: 17109335
Drug: Vaccine (rAd5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine (rAd5 vector HIV-1 candidate vaccine)
Study: 11758237
Drug: Meropenem 500
Normalized name: meropenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 500 mg every 12 hours (or 1g every 12 hours if necessary)
Study: 31711605
Drug: i.v. dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. dexamethasone 8 mg
Study: 24067888
Drug: Neridronate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neridronate (100 mg, monthly i.v.)
Study: 24067888
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg, standard therapy)
Study: 20831543
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 or 30 mg daily) for 3 months
Study: 20831543
Drug: Pioglitazone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone treatment in post-menopausal women
Study: 12135281
Drug: Oral ARTS
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ARTS (135 mg; 352 micromol)
Study: 12135281
Drug: Oral DHA
Normalized name: Atabex DHA Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral DHA (120 mg; 422 micromol)
Study: 12135281
Drug: Hepatic bioavailability
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic bioavailability of ARTS (39 microM)
Study: 12135281
Drug: Hepatic bioavailability
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic bioavailability of DHA in ARTS perfusions (35 microM)
Study: 18691193
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (no Rx)
Study: 15231013
Drug: Raloxifene (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (combined doses of 60 mg/day and 120 mg/day)
Study: 10955700
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 100 microg daily
Study: 10955700
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 200 microg daily
Study: 10999870
Drug: Evening medication
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening medication (all groups)
Study: 10999870
Drug: Morning medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning medication (all groups)
Study: 31828172
Drug: Shenqi pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi pollen capsules (SPCs) for 7 weeks
Study: 31828172
Drug: Shenqi pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi pollen capsules (SPCs)
Study: 18332764
Drug: Immediate placement
Normalized name: IR DIP 10 1 % Iodine Replacement Teat Dip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate placement condition (46 implants)
Study: 15726322
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving systemic antimicrobial treatment
Study: 15726322
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without prior antibiotic treatment
Study: 12904977
Drug: Lithium augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium augmentation therapy
Study: 8932071
Drug: 10 units
Normalized name: Omnipod GO 10 Units/Day Pods
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 units heparin/ml saline (HS)
Study: 1859059
Drug: Albuterol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (100 micrograms/puff, three times two puffs)
Study: 27206549
Drug: Arabinoxylan-oligosaccharide (AXOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arabinoxylan-oligosaccharide (AXOS) 4 × 9.4 g
Study: 27206549
Drug: Maltodextrin (placebo)
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maltodextrin (placebo) 4 × 10 g
Study: 3294614
Drug: Captopril at
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril at a dose of 25 mg twice a day
Study: 3294614
Drug: Nadolol at
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol at a dose of 80 mg once a day
Study: 3294614
Drug: Frusemide at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide at a dose of 25 mg once a day
Study: 24106141
Drug: Cadazolid (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadazolid (multiple doses)
Study: 22800086
Drug: High-dose antioxidant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose antioxidant tablets
Study: 20849868
Drug: Protein shake
Normalized name: Ensure High Protein Shake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein shake (AUC=37,024±3518nmol/L min)
Study: 20849868
Drug: Fat shake
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fat shake (AUC=35,977±3562nmol/L min)
Study: 20849868
Drug: Carbohydrate shake
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate shake (AUC=47,310±3667nmol/L min)
Study: 20849868
Drug: Water (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (control condition) (AUC=32,784±1683nmol/L min)
Study: 11473863
Drug: Early reversal
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early reversal with neostigmine (50 microg/kg) and glycopyrrolate (10 microg/kg) at 2 min after 1.5 mg/kg rapacuronium
Study: 11473863
Drug: Late reversal
Normalized name: edrophonium chloride Injectable Solution [Reversol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late reversal with neostigmine (50 microg/kg) and glycopyrrolate (10 microg/kg) at 25% T1 recovery after 1.5 mg/kg rapacuronium
Study: 7825998
Drug: Methylprednisolone at
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone at 30 mg/kg i.v. for 3 days followed by 20 mg/kg for 4 days
Study: 3387687
Drug: Tartrazine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tartrazine (up to 25 mg)
Study: 3387687
Drug: Tartrazine (50-3,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tartrazine (50-3,000 mg)
Study: 14633567
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia (group G, n = 10)
Study: 8478309
Drug: Dirithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin (500 mg, two tablets once daily)
Study: 24833256
Drug: Comparator antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator antibiotics
Study: 3709640
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg disopyramide i.v.
Study: 3709640
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg atenolol i.v.
Study: 25720546
Drug: Oral fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral fluconazole 150 mg
Study: 21146678
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clopidogrel
Study: 29442148
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg ticagrelor
Study: 23102968
Drug: 9-phage cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-phage cocktail at a dose of 3×10(7) plaque-forming units
Study: 23102968
Drug: 9-phage cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9-phage cocktail (both doses)
Study: 18613991
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention (specialty advice and evidence-based messages regarding medication management for cardiovascular risk)
Study: 11927130
Drug: Subcutaneous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous unfractionated heparin (UH) administered in two to three subcutaneous doses adjusted to activated partial thromboplastin time (APTT)
Study: 30979042
Drug: Low-Intensity Cognitive
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Cognitive Behavior Therapy (LI-CBT) mHealth-supported intervention
Study: 21268101
Drug: Trospium XR
Normalized name: trospium Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospium XR 60 mg once daily for 12 weeks
Study: 18955519
Drug: BILR 355
Approvals — FDA: no, EMA: no, PMDA: no
Description: BILR 355 coadministered with 100 mg ritonavir (RTV) at doses of 5 to 50 mg in a polyethylene glycol solution or 50 to 250 mg as tablets, and 150 mg BID coadministered with 100 mg RTV QD or BID.
Study: 9242943
Drug: Traditional dialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional dialysis using dialyzers with a urea clearance of 170‐180 ml/min
Study: 9242943
Drug: All hemodialysis
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All hemodialysis treatments
Study: 2598970
Drug: Intravenous nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicardipine (D3 nicardipine)
Study: 2598970
Drug: Intravenous unlabelled
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unlabelled nicardipine (D0 nicardipine)
Study: 18754014
Drug: Enteral sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral sterile water (up to 50 ml kg(‐1) per day for 7 days)
Study: 15317632
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy for insomnia (5 sessions, 7 weeks)
Study: 26210642
Drug: ISIS‐APO(a)Rx 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS‐APO(a)Rx 200 mg (6 doses)
Study: 26210642
Drug: ISIS‐APO(a)Rx 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS‐APO(a)Rx 300 mg (6 doses)
Study: 26210642
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 doses)
Study: 12723759
Drug: Goshajinkigan, 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goshajinkigan, 7.5 g/day for 3 months
Study: 2127040
Drug: Pentoxifylline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (2 X 600 mg/d)
Study: 2127040
Drug: Pentoxifylline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (2 X 600 mg/d) and psychological training
Study: 12202415
Drug: Intramuscular hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hCG
Study: 12202415
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen added to progesterone
Study: 30183430
Drug: Electromagnetic transduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electromagnetic transduction therapy (EMTT) + Extracorporeal shock wave therapy (ESWT)
Study: 30183430
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT) with sham-EMTT
Study: 25744274
Drug: Paricalcitol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (2 µg/day) combined with a liberal sodium diet (∼200 mmol Na(+)/day)
Study: 25744274
Drug: Paricalcitol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paricalcitol (2 µg/day) combined with dietary sodium restriction (target: 50 mmol Na(+)/day)
Study: 22567139
Drug: Tablets
Normalized name: Mesna Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets
Study: 11830525
Drug: IFN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN treatment among patients with Δ13
Study: 2632716
Drug: Alcohol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.75 g/kg body weight, diluted in orange juice)
Study: 31636806
Drug: L-carnitine-L-tartrate 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine-L-tartrate 1500 mg per day (n = 11)
Study: 21615472
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied to half of each IH once every other night for 16 weeks
Study: 17285204
Drug: Tropisetron 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 0.5 mg/m2
Study: 17285204
Drug: Tropisetron 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 1.0 mg/m2
Study: 17285204
Drug: Tropisetron 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 1.5 mg/m2
Study: 17285204
Drug: Tropisetron 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 2.0 mg/m2
Study: 17285204
Drug: Tropisetron (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (all doses)
Study: 17285204
Drug: Tropisetron (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (0.5, 1.0, 1.5, 2.0 mg/m2)
Study: 17285204
Drug: Tropisetron (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron (0.5 mg/m2)
Study: 2207824
Drug: Etomidate (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.2 mg/kg)
Study: 2545455
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol (500 micrograms and above)
Study: 144508
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of sodium aurothiomalate (150 mg weekly)
Study: 144508
Drug: Conventional doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doses of sodium aurothiomalate (50 mg weekly)
Study: 25396334
Drug: 80 kVp/60
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 kVp/60 mL CCTA
Study: 25396334
Drug: 100 kVp/60
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 kVp/60 mL CCTA
Study: 22994579
Drug: Nutraceutical combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical combination without Orthosiphon stamineus
Study: 19183308
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (2 g fat, 320 kcal)
Study: 19183308
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (38 g fat, 640 kcal)
Study: 10690130
Drug: DCLHb 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb 100 mg kg‐1 i.v.
Study: 10690130
Drug: DCLHb 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCLHb 200 mg kg‐1 i.v.
Study: 23344769
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg rt-PA (group A)
Study: 23344769
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg rt-PA (group B)
Study: 16759048
Drug: Salvage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage therapy with less daily doses
Study: 11732951
Drug: Nebulized isotonic
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized isotonic sodium chloride solution, 1 mL (Control)
Study: 9209775
Drug: Sumatriptan suppository
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan suppository 12.5 mg
Study: 9209775
Drug: Sumatriptan suppository
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan suppository 25 mg
Study: 9209775
Drug: Sumatriptan suppository
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan suppository 50 mg
Study: 9209775
Drug: Sumatriptan suppository
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan suppository 100 mg
Study: 9209775
Drug: Sumatriptan suppository
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sumatriptan suppository 50 mg (twice a day for 11 doses)
Study: 9209775
Drug: Placebo suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppository (twice a day for 11 doses)
Study: 8480688
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg Zn (as gluconate)/d for 60 days
Study: 3304688
Drug: VAP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAP plus 2 years of oral maintenance chemotherapy
Study: 22019520
Drug: TG4010 plus
Normalized name: TG4010
DrugBank: TG4010 (DB06584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG4010 plus chemotherapy
Study: 26727163
Drug: TG4010 plus
Normalized name: TG4010
DrugBank: TG4010 (DB06584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG4010 plus chemotherapy (TrPAL ≤ ULN)
Study: 26727163
Drug: TG4010 plus
Normalized name: TG4010
DrugBank: TG4010 (DB06584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG4010 plus chemotherapy (TrPAL > ULN)
Study: 24598493
Drug: No root
Approvals — FDA: no, EMA: no, PMDA: no
Description: No root canal preparation (Subgroup 2.3)
Study: 23141853
Drug: Percutaneous intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous intervention plus optimal medical therapy (PCI)
Study: 23141853
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy (MED) alone
Study: 11021737
Drug: Topotecan (2.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan (2.3 mg/m2 per day for 5 days every 21 days) with ranitidine (150 mg twice daily for 4 days before day 1 of one of the first two courses and 150 mg given 2 h before the first topotecan dose)
Study: 6471773
Drug: No beta-Interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-Interferon treatment
Study: 6471773
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (adriamycine, cyclophosphamide, vincristine, dacarbazine)
Study: 30051507
Drug: Smartphone application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone application for Cognitive Behavioral Therapy (CBT)
Study: 26863155
Drug: trans‐resveratrol‐based supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: trans‐resveratrol‐based supplement (Longevinex®)
Study: 22933049
Drug: Epilepax® (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epilepax® (test formulation)
Study: 15358571
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (CS) applied for 48 hours before prick-testing.
Study: 15358571
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of methylprednisolone immediately after prick-testing.
Study: 18495436
Drug: Ziprasidone IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone IM 2 mg
Study: 8046805
Drug: Fixed-schedule therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-schedule therapy (standard course of chlordiazepoxide four times daily with additional medication as needed)
Study: 3054280
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg before test meals
Study: 30086709
Drug: 0.75 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 μg/kg DEX
Study: 30086709
Drug: 1 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/kg DEX